Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Larosa

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Critical Care Medicine|March 19, 2016
Long-Term Quality of Life Among Survivors of Severe Sepsis: Analyses of Two International TrialsSachin Yende, Shamly Austin, Andrew Rhodes, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 18, 2005
Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomalleiSteven P LaRosa, Steven M Opal, Barbara Utterback, et al.
Shock (Augusta, Ga.)|February 11, 2004
Effects of drotrecogin alfa (activated) in human endotoxemiaAndre C Kalil, Susette M Coyle, John Y Um, et al.
BMJ Open|January 6, 2026
Hemopurifier device in patients with solid tumours who have stable or progressive disease while on a treatment that includes pembrolizumab or nivolumab: protocol for an Australian safety, feasibility and dose-finding studyMichael P Brown, Marco Matos, Stephen Clarke, et al.
International Journal of Molecular Sciences|July 15, 2026
Increased Mannosylation of Extracellular Vesicles in Long COVID Plasma as a Binding Target for <i>Galanthus nivalis</i> Agglutinin (GNA) Affinity ResinMiguel A Pesqueira Sanchez, Rosalia de Necochea Campion, Thomas Dalhuisen, et al.
Biorxiv : the Preprint Server for Biology|December 3, 2025
Increased mannosylation of extracellular vesicles in Long COVID plasma provides a potential therapeutic target for <i>Galanthus nivalis</i> agglutinin (GNA) affinity resinMiguel A Pesqueira Sanchez, Rosalia de Necochea Campion, Thomas Dalhuisen, et al.
Critical Care Medicine|December 17, 2013
Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*Gordon R Bernard, Bruno Francois, Jean-Paul Mira, et al.
Critical Care Medicine|September 23, 2003
The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and resultsJean-François Dhainaut, Pierre-François Laterre, Steven P LaRosa, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 28, 2003
Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated)Steven M Opal, Gary E Garber, Steven P LaRosa, et al.
JAMA|March 21, 2013
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trialSteven M Opal, Pierre-Francois Laterre, Bruno Francois, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Critical Care Medicine|March 19, 2016
Long-Term Quality of Life Among Survivors of Severe Sepsis: Analyses of Two International TrialsSachin Yende, Shamly Austin, Andrew Rhodes, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 18, 2005
Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomalleiSteven P LaRosa, Steven M Opal, Barbara Utterback, et al.
Shock (Augusta, Ga.)|February 11, 2004
Effects of drotrecogin alfa (activated) in human endotoxemiaAndre C Kalil, Susette M Coyle, John Y Um, et al.
BMJ Open|January 6, 2026
Hemopurifier device in patients with solid tumours who have stable or progressive disease while on a treatment that includes pembrolizumab or nivolumab: protocol for an Australian safety, feasibility and dose-finding studyMichael P Brown, Marco Matos, Stephen Clarke, et al.
International Journal of Molecular Sciences|July 15, 2026
Increased Mannosylation of Extracellular Vesicles in Long COVID Plasma as a Binding Target for <i>Galanthus nivalis</i> Agglutinin (GNA) Affinity ResinMiguel A Pesqueira Sanchez, Rosalia de Necochea Campion, Thomas Dalhuisen, et al.
Biorxiv : the Preprint Server for Biology|December 3, 2025
Increased mannosylation of extracellular vesicles in Long COVID plasma provides a potential therapeutic target for <i>Galanthus nivalis</i> agglutinin (GNA) affinity resinMiguel A Pesqueira Sanchez, Rosalia de Necochea Campion, Thomas Dalhuisen, et al.
Critical Care Medicine|December 17, 2013
Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*Gordon R Bernard, Bruno Francois, Jean-Paul Mira, et al.
Critical Care Medicine|September 23, 2003
The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and resultsJean-François Dhainaut, Pierre-François Laterre, Steven P LaRosa, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 28, 2003
Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated)Steven M Opal, Gary E Garber, Steven P LaRosa, et al.
JAMA|March 21, 2013
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trialSteven M Opal, Pierre-Francois Laterre, Bruno Francois, et al.
Pageof 4